News
IMMP
3.630
-5.47%
-0.210
Weekly Report: what happened at IMMP last week (0928-1002)?
Weekly Report · 5d ago
Immutep Limited - Depositary Receipt Price Target Increased by 917.93% to $69.75
NASDAQ · 10/02 09:57
Immutep receives A$856,669 cash rebate from Australia R&D tax incentive program
TipRanks · 09/30 12:25
Immutep Receives A$856,669 Cash Rebate From Australian Federal Government’s R&D Tax Incentive Program
Benzinga · 09/30 12:06
Weekly Report: what happened at IMMP last week (0921-0925)?
Weekly Report · 09/28 09:54
Upcoming Stock Splits This Week (September 28 to October 2) – Stay Invested
TipRanks · 09/27 17:43
Immutep Resets ADS Ratio to Bolster Nasdaq Listing Compliance
TipRanks · 09/22 10:36
Immutep announces 1-for-20 ADS ratio change
Seeking Alpha · 09/21 13:06
Immutep Changes ADS Ratio From One ADS Representing 10 Shares To One ADS Representing 200 Shares, Effective September 28
Benzinga · 09/21 12:03
Weekly Report: what happened at IMMP last week (0914-0918)?
Weekly Report · 09/21 09:54
Change to American Depositary Share Ratio
Barchart · 09/21 07:00
*Immutep Target Price Cut 14% to A$0.07/Share by Bell Potter>IMM.AU
Dow Jones · 09/15 01:20
Immutep Gets a New Bull at Jefferies -- Market Talk
Dow Jones · 09/15 01:09
*Immutep Target Price Raised to A$0.08/Share From A$0.04/Share by Jefferies>IMM.AU
Dow Jones · 09/15 00:12
*Immutep Raised to Buy From Hold by Jefferies >IMM.AU
Dow Jones · 09/15 00:12
Bell Potter Remains a Hold on Immutep Ltd (PRRUF)
TipRanks · 09/14 23:35
Weekly Report: what happened at IMMP last week (0907-0911)?
Weekly Report · 09/14 09:57
Immutep provides update on development strategy for eftilagimod alfa
TipRanks · 09/11 12:15
Weekly Report: what happened at IMMP last week (0831-0904)?
Weekly Report · 09/07 09:53
Immutep Posts Higher FY2026 Loss Despite New Licensing Revenue
TipRanks · 09/02 10:28
More
Webull provides a variety of real-time IMMP stock news. You can receive the latest news about Immutep through multiple platforms. This information may help you make smarter investment decisions.
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.